Quick Takeaways: Why It Matters? PetVivo’s preliminary macaque studies add early evidence for Spryng’s potential in osteoarthritis management, combining mobility improvements with encouraging local tissue-response findings. The data could support further development of its inje...
Quick Takeaways: Why It Matters? CannEpil’s MUMS designation could give Endovia and Lupvindol an early-mover advantage in veterinary oncology pain management, particularly if the conditional pathway enables faster commercialization. A potential 2027 launch may expand cannabinoi...
Quick Takeaways: Why It Matters? The FDA’s Emergency Use Authorization for Simparica Trio to treat New World screwworm (NWS) larvae in dogs gives veterinarians a convenient, oral option that can be used alongside existing livestock tools (e.g., Dectomax...
Quick Takeaways: Why It Matters? Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works a...
Quick Takeaways: Why It Matters? With 138 horses across eight practices showing significantly better outcomes and nearly triple the odds of returning to prior performance, the data should help veterinarians justify using equicenta CTM as a convenient, regenerative alternative to harvesting...
Quick Takeaways: Why It Matters? The launch should help Zomedica make PulseVet easier to use in everyday practice by improving patient and staff comfort, potentially reducing anxiety-driven resistance and making clinics more willing to adopt or keep using shock wave therapy for equine and ...
Quick Takeaways: Why It Matters? Parnell’s 50 mL PropofolVet Multidose should help veterinary practices match vial size to procedure volume, cutting waste and improving inventory efficiency while keeping the same propofol use cases and 28-day, no-refrigeration convenience. Marketwise, the ...
Quick Takeaways: Why It Matters? The deal broadens PetIQ’s product mix into a higher-value mobility category that can be cross-sold through retail, e-commerce and distribution channels, potentially increasing average basket size and strengthening PetIQ’s positioning as a branded pet health...
Quick Takeaways: Why It Matters? By terminating the PrecisePRP arrangement with VetStem, PetVivo removes outstanding invoices, royalties and milestone overhangs from a non-core product line, which should simplify the story for investors and management while freeing attention and capital fo...
Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
